Evidence map›Paper›PMID 34780023›Full record

ReviewReproductive sciences (Thousand Oaks, Calif.)2022

Self-Monitoring of Urinary Hormones in Combination with Telemedicine - a Timely Review and Opinion Piece in Medically Assisted Reproduction.

Roger J Hart, Thomas D'Hooghe, Eline A F Dancet, Ramón Aurell, Bruno Lunenfeld, Raoul Orvieto, Antonio Pellicer, Nikolaos P Polyzos, Wenjing Zheng

Open access · hybridAbstract readReview
In one paragraph

Review in Reproductive sciences (Thousand Oaks, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 6 countries.

Roger J HartDivision of Obstetrics and Gynaecology, The University of Western Australia & Fertility Specialists of Western Australia, Perth, WA, Australia.
Thomas D'HoogheDepartment of Development and Regeneration, KU Leuven, Leuven, Belgium.
Eline A F DancetDepartment of Development and Regeneration, KU Leuven, Leuven, Belgium.
Ramón AurellIVF Unit, Fertility Campus Hospital Quirónsalud Barcelona, Barcelona, Spain.
Bruno LunenfeldFaculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
Raoul OrvietoInfertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, Israel.
Antonio PellicerInstituto de Investigación Sanitaria La Fe, Valencia, Spain.
Nikolaos P PolyzosDepartment of Obstetrics, Gynecology and Reproductive Medicine, Dexeus Mujer, Dexeus University Hospital, Barcelona, Spain.
Wenjing ZhengGlobal Medical Affairs Fertility, R&D Healthcare, the healthcare business of Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany. wenjing.zheng@merckgroup.com.ORCID 0000-0003-0799-3474
Bar-Ilan University · ILGhent University · BEHospital Quirónsalud Barcelona · ESInstituto de Investigación Sanitaria La Fe · ESLeuven Institute for Fertility and Embryology · BEMerck (Germany) · DETel Aviv University · ILThe University of Western Australia · AUYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cycle monitoring via ultrasound and serum-based hormonal assays during medically assisted reproduction (MAR) can provide information on ovarian response and assist in optimizing treatment strategies in addition to reducing complications such as ovarian hyperstimulation syndrome (OHSS). Two surveys conducted in 2019 and 2020, including overall 24 fertility specialists from Europe, Asia and Latin America, confirmed that the majority of fertility practitioners routinely conduct hormone monitoring during MAR. However, blood tests may cause inconvenience to patients. The reported drawbacks of blood tests identified by the survey included the validity of results from different service providers, long waiting times and discomfort to patients due to travelling to clinics for tests and repeated venepunctures. Historically, urine-based assays were used by fertility specialists in clinics but were subsequently replaced by more practical and automated serum-based assays. A remote urine-based hormonal assay could be an alternative to current serum-based testing at clinics, reducing the inconvenience of blood tests and the frequency of appointments, waiting times and patient burden. Here we provide an overview of the current standard of care for cycle monitoring and review the literature to assess the correlation between urine-based hormonal assays and serum-based hormonal assays during MAR. In addition, in this review, we discuss the evidence supporting the introduction of remote urine-based hormonal monitoring as part of a novel digital health solution that includes remote ultrasound and tele-counselling to link clinics and patients at home.

Indexed as

Ovarian Hyperstimulation SyndromeTelemedicineFemaleFertilization in VitroHormonesHumansReproductionHormonesHome-based monitoringIn vitro fertilization (IVF)Medically assisted reproduction (MAR)Remote urine-based hormonal monitoringSelf-monitoringTelemedicine

Identifiers

PMID34780023
PMCPMC8592080
OpenAlexW3213601843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.